Antonceptivos combinados nuevos reducen riesgo de cancer de ovario

Newer Combination Hormonal Contraceptives Linked to Lower Ovarian Cancer Risk

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM

Use of combination hormonal contraceptives continues to be associated with reduced risk for ovarian cancer in younger women, according to a study in The BMJ.

Using Danish registries, researchers studied nearly 1.9 million women aged 15–49 between 1995 and 2014. The incidence rate of ovarian cancer was 4.3 per 100,000 person-years among women who'd ever used hormonal contraceptives, versus 7.5 per 100,000 among never-users.

After multivariable adjustment, use of hormonal contraceptives was associated with a 34% reduced risk for ovarian cancer. The risk reduction was greater with longer duration of use, and it persisted years after stopping use. Of note, most hormonal contraceptives were combined oral contraceptives, and progestogen-only contraceptives were not associated with reduced cancer risk.

The researchers conclude, "Contemporary combined hormonal contraceptives are still associated with a reduced risk of ovarian cancer in women of reproductive age, with patterns similar to those seen with older combined oral products."

The BMJ article (Free)

Background: NEJM Journal Watch Women's Health coverage of durable cancer prevention with combination oral contraceptives (Your NEJM Journal Watch registration required)

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 2224-0654
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.